News | April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
The business and product range of Ipca and that of Unichem complements each others business and product range
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
The acquisition is a crucial step in LTS' strategy to broaden its portfolio of drug delivery platforms.
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Healthcare leaders are heavily investing in AI or plan to do so for both critical decision support and operational efficiency, helping tackle staff shortages
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
From cancer research to diagnostic solutions
Subscribe To Our Newsletter & Stay Updated
